ARS Pharmaceuticals (NASDAQ:SPRY) Announces Quarterly Earnings Results

ARS Pharmaceuticals (NASDAQ:SPRY) released its quarterly earnings data on Thursday. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.61, Zacks reports.

ARS Pharmaceuticals Stock Up 24.2 %

Shares of NASDAQ:SPRY traded up $2.82 during trading on Thursday, hitting $14.47. The stock had a trading volume of 4,254,858 shares, compared to its average volume of 1,017,073. The company has a market capitalization of $1.41 billion, a PE ratio of -29.07 and a beta of 1.03. The firm’s fifty day moving average is $11.98 and its 200 day moving average is $13.03. ARS Pharmaceuticals has a 12 month low of $7.55 and a 12 month high of $18.51.

Analyst Ratings Changes

SPRY has been the subject of several analyst reports. Scotiabank started coverage on shares of ARS Pharmaceuticals in a research report on Friday, March 7th. They set a “sector outperform” rating and a $30.00 price target for the company. Oppenheimer started coverage on shares of ARS Pharmaceuticals in a report on Monday, February 10th. They set an “outperform” rating and a $40.00 target price for the company. Raymond James boosted their price target on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 14th. William Blair reiterated an “outperform” rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Finally, Leerink Partners boosted their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $31.00.

Insider Activity at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, Director Laura Shawver sold 50,000 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $12.31, for a total transaction of $615,500.00. Following the completion of the transaction, the director now owns 210,346 shares of the company’s stock, valued at approximately $2,589,359.26. This trade represents a 19.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold 149,600 shares of company stock worth $1,726,516 over the last ninety days. 40.10% of the stock is owned by corporate insiders.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.